Skip to main content
Top
Published in: Reactions Weekly 1/2012

01-03-2012 | Case report

Clofarabine/cyclophosphamide/etoposide

Hyperbilirubinaemia, zygomycosis and multiple organ failure: case report

Published in: Reactions Weekly | Issue 1/2012

Login to get access

Excerpt

An event is serious (FDA MedWatch definition) when the patient outcome is:
  • death
  • life-threatening
  • hospitalisation
  • disability
  • congenital anomaly
  • requires intervention to prevent permanent impairment or damage
Literature
1.
go back to reference Inaba H, Bhojwani D, Pauley JL, Pei D, Cheng C, Metzger ML, Howard SC, Rubnitz JE, Sandlund JT, Ribeiro RC, Leung W, Campana D, Pui C-H, Jeha S.Combination chemotherapy with clofarabine, cyclophosphamide, and etoposide in children with refractory or relapsed haematological malignancies. British Journal of Haematology 156: 275-279, No. 2, Jan 2012. Available from: URL: http://dx.doi.org/10.1111/j.1365-2141.2011.08847.x - USA Inaba H, Bhojwani D, Pauley JL, Pei D, Cheng C, Metzger ML, Howard SC, Rubnitz JE, Sandlund JT, Ribeiro RC, Leung W, Campana D, Pui C-H, Jeha S.Combination chemotherapy with clofarabine, cyclophosphamide, and etoposide in children with refractory or relapsed haematological malignancies. British Journal of Haematology 156: 275-279, No. 2, Jan 2012. Available from: URL: http://​dx.​doi.​org/​10.​1111/​j.​1365-2141.​2011.​08847.​x - USA
Metadata
Title
Clofarabine/cyclophosphamide/etoposide
Hyperbilirubinaemia, zygomycosis and multiple organ failure: case report
Publication date
01-03-2012
Publisher
Springer International Publishing
Published in
Reactions Weekly / Issue 1/2012
Print ISSN: 0114-9954
Electronic ISSN: 1179-2051
DOI
https://doi.org/10.2165/00128415-201213920-00050

Other articles of this Issue 1/2012

Reactions Weekly 1/2012 Go to the issue

Case report

Icatibant

Case report

Levonorgestrel

Case report

Cyclophosphamide

Case report

Corticotropin

Case report

Busulfan